Early Immunogenicity Risk Mitigation
Poster Sep 10, 2014
Chloé Ackaert, Brecht Hoedemaekers, Sofie Pattijn and Philippe Stas
The ability of a drug candidate to induce an unwanted immune response can be a significant hurdle during drug development and a reason for product failures. Unwanted immunogenicity can cause loss of efficacy, altered pharmacodynamics and stability problems.
Implementing early immunogenicity assessment strategies using tools like in silico T cell epitope prediction and in vitro T cell assays can contribute significantly to the successful outcome of drug development programs and reduce the number of product failures.
Cerebral Malaria Insights: Pathogenesis, Host Parasite Interactions including Host ResistancePoster
Cerebral malaria is a dreadful disease transmitted by mosquito. The major preventive approach is focused more in vector control than development of anti-malarial drug. The purpose of this presentation is to analyze different aspects of disease manifestations including clinical symptoms and pathogenesis in the context of mosquito borne infections in different geographical regions of the world.READ MORE
Amoebic Meningoencephalitis: Etiology, Infection and PreventionPoster
The presentation covers the different types of organisms that can cause amoebic meningioencephalitis. The two main types focused on are primary amoebic meningioencephalitis and granulomatous amoebic meningioencephalitis. The method of transmission and target hosts are vastly different. Prevention of these diseases is imperfect at best, as complete avoidance is the only way to not contract the disease.READ MORE
Depressive Symptoms Related to Biological Markers of Immune Functioning among Young People with HIVPoster
Youth living with HIV (YLWH) are at risk for depression. This study aimed to identify trends in depressive symptoms for YLWH in a specialty-care clinic and follow up clinical treatment procedures.READ MORE